Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial

Brown, Paul D.; Pugh, S.; Laack, Nadia N.; Wefel, Jeffrey S.; Khuntia, Deepak; Meyers, Christina; Choucair, Ali; Fox, Sherry; Suh, John H.; Roberge, David; Kavadi, Vivek S.; Bentzen, Søren M.; Mehta, Minesh P.; Bruner, Deborah Watkins; (RTOG), for the Radiation Therapy Oncology Group

doi:10.1093/neuonc/not114

articleNeuro-OncologyAug 16, 2013BRONZE OA

Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial

PDPaul D. Brown SPS. Pugh NNNadia N. Laack JSJeffrey S. Wefel DKDeepak Khuntia

The University of Texas MD Anderson Cancer Center · Radiation Oncology Associates · +12 more institutions

PubMed

Indexed incrossrefpubmed

Abstract

Background

To determine the protective effects of memantine on cognitive function in patients receiving whole-brain radiotherapy (WBRT).

Methods

Adult patients with brain metastases received WBRT and were randomized to receive placebo or memantine (20 mg/d), within 3 days of initiating radiotherapy for 24 weeks. Serial standardized tests of cognitive function were performed.

Citation impact

938

total citations

FWCI: 36.87
Percentile: 100%
References: 39

Citations per year

Authors

15

Topics & keywords

Topics

Keywords

Memantine
Medicine
Placebo
Hazard ratio
Randomized controlled trial
Cognition
Clinical endpoint
Cognitive decline

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.